Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back to main page
NEW:
Evidence
Click below to explore the latest additions to VERI
Click below to explore the latest additions to VERI
Biomarkers (5)
Genes (3)
Drugs (7)
Tests (3)
Evidence (43)
Biomarker (27)
AGK-BRAF fusion
ALK positive
BRAF V600
BRAF mutation
EGFR L858R
EGFR T790M
EGFR exon 19 deletion
EGFR mutation
EGFR negative
ER positive
ERBB3 expression
FGFR2-BICC1 fusion
FOLR1 expression
HER-2 expression
HER-2 positive
HR positive
HRD
IDH1 mutation
IDH2 mutation
KRAS G12C
LDH elevation
MGMT unmethylation
MSI-H/dMMR
PD-L1 expression
PTEN overexpression
RET rearrangement
RSPO3 fusion
Cancer type (21)
Breast Cancer
Cervical Cancer
Cholangiocarcinoma
Colorectal Cancer
Endometrial Cancer
Gastrointestinal Stromal Tumor
Glioblastoma
Glioma
HER2 Negative Breast Cancer
HER2 Positive Breast Cancer
Lung Adenocarcinoma
Lung Cancer
Lung Non-Squamous Non-Small Cell Cancer
Melanoma
Non Small Cell Lung Cancer
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Papillary Carcinoma
Therapy (35)
AZD3759
BL-B01D1
DAY101
DF1001
EGFR inhibitor
FORE-8394
G1T38
OTS514
PRT811
STRO-002
U3-1402
UCPVax
abemaciclib
afatinib
alectinib
axitinib
befotertinib
bevacizumab
dalpiciclib
docetaxel
dostarlimab-gxly
fam-trastuzumab deruxtecan-nxki
nivolumab
osimertinib
palbociclib
pembrolizumab
pembrolizumab + BCA101
pembrolizumab + CGX1321
pembrolizumab + pemigatinib
pralsetinib
sacituzumab govitecan-hziy
sotorasib + OTS514
talazoparib
toripalimab
trastuzumab + pertuzumab
PD-L1 expression
PD-L1 expression
Non Small Cell Lung Cancer
NSCLC
nivolumab
Sensitive: B - Late Trials
Bristol-Myers Squibb Press Release - 2 days
nivolumab
Sensitive: B - Late Trials
Bristol-Myers Squibb Press Release - 2 days
AGK-BRAF fusion
AGK-BRAF fusion
Melanoma
Melanoma
FORE-8394
Resistant: C4 – Case Studies
ASCO 2023 - 3 days
FORE-8394
Resistant: C4 – Case Studies
ASCO 2023 - 3 days
ERBB3 expression
ERBB3 expression
Breast Cancer
Breast Cancer
U3-1402
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
U3-1402
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
BRAF V600
BRAF V600
Thyroid Gland Anaplastic Carcinoma
Thyroid Gland Anaplastic Carcinoma
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
MGMT unmethylation
MGMT unmethylation
Glioblastoma
GBM
UCPVax
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
UCPVax
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
BRAF V600
BRAF V600
Glioma
Glioma
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
EGFR mutation
EGFR mutation
Non Small Cell Lung Cancer
NSCLC
BL-B01D1
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
BL-B01D1
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
HER-2 expression
HER-2 expression
Lung Cancer
Lung Cancer
DF1001
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
DF1001
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
BRAF V600
BRAF V600
Ovarian Cancer
Ovarian Cancer
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
BRAF V600
BRAF V600
Thyroid Gland Papillary Carcinoma
Thyroid Gland Papillary Carcinoma
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
KRAS G12C
KRAS G12C
Non Small Cell Lung Cancer
NSCLC
docetaxel
Resistant: C3 – Early Trials
Lung Cancer - 3 days
docetaxel
Resistant: C3 – Early Trials
Lung Cancer - 3 days
ALK positive
ALK positive
Non Small Cell Lung Cancer
NSCLC
alectinib
Sensitive: C3 – Early Trials
Future Medicine - 3 days
alectinib
Sensitive: C3 – Early Trials
Future Medicine - 3 days
PD-L1 expression
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
SCCHN
pembrolizumab + BCA101
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
pembrolizumab + BCA101
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
FOLR1 expression
FOLR1 expression
Ovarian Cancer
Ovarian Cancer
STRO-002
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
STRO-002
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
HR positive
HR positive
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
dalpiciclib
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
dalpiciclib
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
RSPO3 fusion
RSPO3 fusion
Gastrointestinal Stromal Tumor
GIST
pembrolizumab + CGX1321
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
pembrolizumab + CGX1321
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
HER-2 positive
HER-2 positive
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
IDH1 mutation
IDH1 mutation
Glioma
Glioma
PRT811
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
PRT811
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
IDH2 mutation
IDH2 mutation
Glioma
Glioma
PRT811
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
PRT811
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
HER-2 expression
HER-2 expression
Breast Cancer
Breast Cancer
DF1001
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
DF1001
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
PTEN overexpression
PTEN overexpression
Squamous Cell Carcinoma of Head and Neck
SCCHN
afatinib
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
afatinib
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
BRAF V600
BRAF V600
Colorectal Cancer
CRC
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
FORE-8394
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
HER-2 positive
HER-2 positive
Colorectal Cancer
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
MSI-H/dMMR
MSI-H/dMMR
Endometrial Cancer
Endometrial Cancer
dostarlimab-gxly
Sensitive: B - Late Trials
ASCO 2023 - 3 days
dostarlimab-gxly
Sensitive: B - Late Trials
ASCO 2023 - 3 days
PD-L1 expression
PD-L1 expression
Cervical Cancer
Cervical Cancer
pembrolizumab
Sensitive: B - Late Trials
ASCO 2023 - 3 days
pembrolizumab
Sensitive: B - Late Trials
ASCO 2023 - 3 days
EGFR mutation
EGFR mutation
Non Small Cell Lung Cancer
NSCLC
AZD3759
Sensitive: B - Late Trials
ASCO 2023 - 3 days
AZD3759
Sensitive: B - Late Trials
ASCO 2023 - 3 days
HRD
HRD
Prostate Cancer
Prostate Cancer
talazoparib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
talazoparib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
HR positive
HR positive
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: B - Late Trials
ASCO 2023 - 3 days
sacituzumab govitecan-hziy
Sensitive: B - Late Trials
ASCO 2023 - 3 days
ER positive
ER positive
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
palbociclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
HR positive
HR positive
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
abemaciclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
abemaciclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
HR positive
HR positive
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
G1T38
Sensitive: B - Late Trials
ASCO 2023 - 3 days
G1T38
Sensitive: B - Late Trials
ASCO 2023 - 3 days
PD-L1 expression
PD-L1 expression
Non Small Cell Lung Cancer
NSCLC
toripalimab
Sensitive: B - Late Trials
ASCO 2023 - 3 days
toripalimab
Sensitive: B - Late Trials
ASCO 2023 - 3 days
KRAS G12C
KRAS G12C
Non Small Cell Lung Cancer
NSCLC
OTS514
Sensitive: D – Preclinical
J Cell Mol Med - 4 days
OTS514
Sensitive: D – Preclinical
J Cell Mol Med - 4 days
KRAS G12C
KRAS G12C
Non Small Cell Lung Cancer
NSCLC
sotorasib + OTS514
Sensitive: D – Preclinical
J Cell Mol Med - 4 days
sotorasib + OTS514
Sensitive: D – Preclinical
J Cell Mol Med - 4 days
FGFR2-BICC1 fusion
FGFR2-BICC1 fusion
Cholangiocarcinoma
Cholangiocarcinoma
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
Front Immunol - 4 days
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
Front Immunol - 4 days
EGFR negative
EGFR negative
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: C3 – Early Trials
Cancer Med - 4 days
bevacizumab
Sensitive: C3 – Early Trials
Cancer Med - 4 days
EGFR L858R
EGFR L858R
Non Small Cell Lung Cancer
NSCLC
befotertinib
Sensitive: B - Late Trials
Lancet Respir Med - 4 days
befotertinib
Sensitive: B - Late Trials
Lancet Respir Med - 4 days
EGFR exon 19 deletion
EGFR exon 19 deletion
Non Small Cell Lung Cancer
NSCLC
befotertinib
Sensitive: B - Late Trials
Lancet Respir Med - 4 days
befotertinib
Sensitive: B - Late Trials
Lancet Respir Med - 4 days
EGFR T790M
EGFR T790M
Lung Adenocarcinoma
LUAD
osimertinib
Resistant: C4 – Case Studies
Gan To Kagaku Ryoho - 5 days
osimertinib
Resistant: C4 – Case Studies
Gan To Kagaku Ryoho - 5 days
BRAF mutation
BRAF mutation
Melanoma
Melanoma
DAY101
Sensitive: C3 – Early Trials
Cancer Chemother Pharmacol - 5 days
DAY101
Sensitive: C3 – Early Trials
Cancer Chemother Pharmacol - 5 days
EGFR mutation
EGFR mutation
Non Small Cell Lung Cancer
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
Sci Rep - 5 days
EGFR inhibitor
Sensitive: C3 – Early Trials
Sci Rep - 5 days
RET rearrangement
RET rearrangement
Non Small Cell Lung Cancer
NSCLC
pralsetinib
Sensitive: C3 – Early Trials
Cancer Res Treat - 6 days
pralsetinib
Sensitive: C3 – Early Trials
Cancer Res Treat - 6 days
LDH elevation
LDH elevation
Renal Cell Carcinoma
RCC
axitinib
Resistant: C3 – Early Trials
Kidney Cancer - 6 days
axitinib
Resistant: C3 – Early Trials
Kidney Cancer - 6 days
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login